Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Frontline Zejula Maintenance Therapy Improves Survival in Advanced Ovarian Cancer
September 29th 2019Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.
Read More
Addition of PARP Inhibitor to Maintenance Therapy May Improve Survival in Ovarian Cancer
September 28th 2019The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.
Read More
Erleada May Extend Subsequent Progression in Men With Castration-Resistant Prostate Cancer
September 28th 2019Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.
Read More
Newly Discovered Biomarkers Suggest Who May Benefit From Liver Cancer Treatment
September 17th 2019Researchers at Roswell Park Comprehensive Cancer Center found a biomarker that may help to determine which patients with hepatocellular carcinoma will respond to treatment with Nexavar, leading to more individualized treatment options.
Read More
'Listen to Your Mother' and Protect Your Skin
September 12th 2019In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a skin cancer survivor who has dealt with many recurrences over the last 30 years and tells others to “listen to your mother” and protect your skin from the sun.
Read More
Medicare Coverage of CAR-T Cell Therapy Opens Patient Access to Life-Saving Treatment
August 17th 2019Following its announcement of covering chimeric antigen receptor-T cell therapy nationwide, the Centers for Medicare and Medicaid Services has now made this highly-priced, but life-saving, treatment available to many who would not otherwise have access to it at their cancer centers.
Read More